Is there a Bearish outlook for Zogenix, Inc. (NASDAQ:ZGNX) this week?

August 9, 2018 - By Ash Maslow

Zogenix, Inc. (NASDAQ:ZGNX) Logo

Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage

Among 2 analysts covering Zogenix (NASDAQ:ZGNX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zogenix has $65 highest and $54 lowest target. $59.50’s average target is 15.65% above currents $51.45 stock price. Zogenix had 2 analyst reports since February 23, 2018 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, July 13. The company was maintained on Friday, February 23 by Leerink Swann. Below is a list of Zogenix, Inc. (NASDAQ:ZGNX) latest ratings and price target changes.

13/07/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $55 New Target: $65 Maintain
23/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $50 New Target: $54 Maintain

The stock decreased 1.81% or $0.95 during the last trading session, reaching $51.45. About 3.46 million shares traded or 366.24% up from the average. Zogenix, Inc. (NASDAQ:ZGNX) has risen 225.58% since August 9, 2017 and is uptrending. It has outperformed by 213.01% the S&P500.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company has market cap of $1.84 billion. The companyÂ’s lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It currently has negative earnings. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.

More notable recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: Nasdaq.com which released: “Zogenix Announces Proposed Public Offering of 6000000 Shares of Common Stock” on August 06, 2018, also Nasdaq.com with their article: “Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)” published on August 01, 2018, Investingnews.com published: “VIDEO — Life Science Update July 2018” on August 07, 2018. More interesting news about Zogenix, Inc. (NASDAQ:ZGNX) were released by: Seekingalpha.com and their article: “Zogenix annouonces pricing of common stock” published on August 08, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” with publication date: August 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.